Centre For Human Drug Research
Leiden, 2333, Netherlands
NCT Number: NCT03609775
A study to investigate the drug-drug interactions between ACT-541468 and ethanol in healthy subjects
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Leiden, 2333, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One tablet of 50 mg ACT-541468 will be administered orally.
Matching ACT-541468 placebo will be administered orally as 1 tablet.
Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
Time frame: Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose
Time frame: Several timepoints on Day 1; for up to 24 hours post-dose
Time frame: Several timepoints on Day 1; for up to 5 hours
Time frame: AEs from Day 1 to Day 2 (EOT/EOS); for up to 2 days post-dose
Time frame: SAEs from Screening to Safety follow up; for up to 14 weeks
Idorsia Pharmaceuticals Ltd.
Industry
A Double-blind, Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details